Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own3.20% Shs Outstand102.34M Perf Week-8.60%
Market Cap5.86B Forward P/E- EPS next Y-0.87 Insider Trans-11.28% Shs Float100.06M Perf Month6.01%
Income-84.60M PEG- EPS next Q0.30 Inst Own67.10% Short Float8.19% Perf Quarter50.08%
Sales88.00M P/S66.58 EPS this Y-221.80% Inst Trans-0.56% Short Ratio4.99 Perf Half Y89.10%
Book/sh4.51 P/B13.97 EPS next Y-155.90% ROA-15.20% Target Price76.33 Perf Year-8.74%
Cash/sh3.39 P/C18.57 EPS next 5Y7.33% ROE-17.40% 52W Range19.51 - 73.72 Perf YTD-0.69%
Dividend- P/FCF- EPS past 5Y12.10% ROI-20.20% 52W High-14.56% Beta1.52
Dividend %- Quick Ratio7.90 Sales past 5Y196.80% Gross Margin- 52W Low222.86% ATR4.00
Employees98 Current Ratio7.90 Sales Q/Q-82.40% Oper. Margin- RSI (14)51.70 Volatility8.24% 5.84%
OptionableYes Debt/Eq0.00 EPS Q/Q-508.30% Profit Margin-96.10% Rel Volume0.63 Prev Close57.02
ShortableYes LT Debt/Eq0.00 EarningsNov 23 AMC Payout- Avg Volume1.64M Price62.99
Recom1.90 SMA20-3.50% SMA5013.99% SMA20050.64% Volume1,023,713 Change10.47%
Nov-19-20Initiated Citigroup Buy $90
May-13-20Initiated RBC Capital Mkts Outperform $62
May-08-20Upgrade Oppenheimer Perform → Outperform $58
Apr-15-20Upgrade Cantor Fitzgerald Neutral → Overweight $55 → $60
Mar-24-20Upgrade SVB Leerink Underperform → Mkt Perform $29
Mar-17-20Initiated Goldman Neutral $45
Jan-21-20Initiated SVB Leerink Underperform $32
Dec-13-19Initiated Oppenheimer Perform
Nov-29-19Reiterated Chardan Capital Markets Buy $45 → $81
Nov-27-19Reiterated B. Riley FBR Buy $59 → $83
Nov-25-19Upgrade Robert W. Baird Neutral → Outperform $70
Oct-24-19Downgrade Robert W. Baird Outperform → Neutral $39
Oct-22-19Reiterated Chardan Capital Markets Buy $32 → $45
Oct-03-19Initiated Robert W. Baird Outperform $39
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Nov-28-20 01:23AM  
Nov-25-20 07:30AM  
Nov-23-20 09:00PM  
05:21PM  
04:00PM  
02:15PM  
Nov-13-20 10:00AM  
09:00AM  
Nov-09-20 07:30AM  
Nov-04-20 07:30AM  
Nov-02-20 04:00PM  
Oct-31-20 06:43AM  
Oct-15-20 05:00PM  
04:12PM  
10:24AM  
Oct-14-20 05:29PM  
Oct-10-20 08:04AM  
Oct-08-20 09:20AM  
07:30AM  
Oct-06-20 10:46AM  
Sep-30-20 04:01PM  
Sep-24-20 04:30PM  
Sep-21-20 05:41AM  
Sep-17-20 11:28PM  
Sep-16-20 04:24PM  
11:48AM  
11:20AM  
10:22AM  
07:30AM  
Sep-10-20 10:37AM  
Sep-08-20 07:30AM  
07:30AM  
Sep-07-20 07:01AM  
Aug-31-20 04:50AM  
Aug-28-20 07:30AM  
Aug-18-20 08:00AM  
07:30AM  
Aug-11-20 07:30AM  
Aug-10-20 07:15AM  
Aug-05-20 04:00PM  
Jul-29-20 07:30AM  
Jul-28-20 07:08PM  
11:59AM  
Jul-24-20 04:10PM  
Jul-18-20 07:17PM  
Jul-09-20 08:19AM  
07:30AM  
Jul-08-20 04:00PM  
10:13AM  
Jun-16-20 09:46PM  
09:30AM  
Jun-02-20 12:35PM  
May-30-20 06:35PM  
May-28-20 07:30AM  
May-24-20 10:10AM  
May-22-20 11:34AM  
May-19-20 07:02AM  
May-10-20 08:20AM  
May-08-20 09:30PM  
May-07-20 04:00PM  
May-01-20 04:00PM  
04:00PM  
Apr-30-20 07:52AM  
Apr-22-20 07:30AM  
Apr-20-20 06:31AM  
Apr-10-20 07:30AM  
Apr-06-20 06:26PM  
10:30AM  
Mar-20-20 02:15PM  
Mar-18-20 08:00PM  
Mar-17-20 04:10PM  
04:10PM  
Mar-15-20 08:30AM  
Mar-10-20 04:16PM  
Mar-03-20 07:30AM  
Mar-02-20 04:00PM  
Feb-13-20 04:47PM  
Feb-12-20 09:37PM  
Feb-07-20 09:36AM  
Feb-06-20 07:47AM  
Feb-05-20 04:00PM  
04:00PM  
07:43AM  
Feb-03-20 01:06PM  
Jan-24-20 05:31AM  
Jan-22-20 04:29PM  
07:30AM  
Jan-21-20 04:30PM  
Jan-16-20 03:55PM  
Jan-11-20 08:00AM  
Jan-10-20 11:51AM  
Jan-06-20 07:30AM  
Jan-02-20 08:00AM  
Dec-27-19 06:06PM  
Dec-26-19 05:27AM  
Dec-24-19 10:00AM  
Dec-23-19 10:21AM  
08:00AM  
Dec-20-19 07:30AM  
Dec-16-19 10:55PM  
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bradshaw CurtChief Scientific OfficerNov 20Sale68.7315,6251,073,9060Nov 23 05:58 PM
Bradshaw CurtChief Scientific OfficerNov 19Sale69.3915,6251,084,21915,625Nov 23 05:58 PM
San Martin JavierChief Medical OfficerNov 19Sale69.3919,5001,353,105130,500Nov 20 06:03 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 09Option Exercise14.5443,505632,563471,173Nov 12 05:49 PM
Myszkowski Kenneth AllenChief Financial OfficerNov 09Sale69.3743,5053,018,071427,668Nov 12 05:49 PM
Anzalone Christopher RichardChief Executive OfficerOct 23Sale58.21100,0005,821,0322,505,237Oct 23 07:35 PM
Myszkowski Kenneth AllenChief Financial OfficerOct 20Option Exercise6.1529,166179,371456,834Oct 22 06:02 PM
Myszkowski Kenneth AllenChief Financial OfficerOct 20Sale54.0429,1661,576,131427,668Oct 22 06:02 PM
Ferrari MauroDirectorOct 09Sale48.0010,000480,00030,971Oct 13 06:01 PM
De Backer MarianneDirectorOct 08Buy50.471,00050,46517,500Oct 26 06:02 PM
Anzalone Christopher RichardChief Executive OfficerAug 13Option Exercise9.9050,000495,0002,655,237Aug 14 06:08 PM
Anzalone Christopher RichardChief Executive OfficerAug 13Sale41.3550,0002,067,5002,605,237Aug 14 06:08 PM
Anzalone Christopher RichardChief Executive OfficerJun 25Sale38.81100,0003,881,0172,605,237Jun 26 06:02 PM
De Backer MarianneDirectorJun 15Buy31.3350015,66516,500Jun 24 06:10 PM
PERRY MICHAEL SDirectorMay 14Option Exercise3.7077,000285,20085,000May 18 06:27 PM
PERRY MICHAEL SDirectorMay 12Sale35.8336,0001,289,8918,000May 13 06:48 PM
Waddill William D.DirectorMay 11Sale36.5426,000950,04028,000May 13 06:45 PM
GIVEN BRUCE DChief Operating OfficerApr 28Option Exercise8.614,19736,131855,831Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 28Sale40.005,101204,040850,730Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 27Option Exercise5.192001,038851,934Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 27Sale40.0030012,000851,634Apr 29 07:19 PM
GIVEN BRUCE DChief Operating OfficerApr 20Option Exercise8.1416,256132,286875,249Apr 22 07:00 PM
GIVEN BRUCE DChief Operating OfficerApr 20Sale40.0023,515940,600851,734Apr 22 07:00 PM
De Backer MarianneDirectorApr 15Buy35.4050017,70016,000Jun 24 06:10 PM
GIVEN DOUGLAS BDirectorApr 14Sale36.8925,000922,250155,925Apr 16 07:47 PM
De Backer MarianneDirectorMar 16Buy23.9450011,97015,500Jun 24 06:10 PM
De Backer MarianneDirectorMar 12Buy24.8050012,40015,000Jun 24 06:10 PM
De Backer MarianneDirectorMar 11Buy28.6050014,30014,500Jun 24 06:10 PM
De Backer MarianneDirectorFeb 28Buy34.3950017,19514,000Jun 24 06:10 PM
De Backer MarianneDirectorFeb 27Buy35.0750017,53513,500Jun 24 06:10 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 25Option Exercise8.8443,445384,145427,668Feb 27 05:41 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 21Option Exercise5.1933,351173,092424,536Jan 23 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 21Sale49.4440,3131,992,925384,223Jan 23 06:15 PM
De Backer MarianneDirectorJan 13Buy54.9550027,47513,000Jun 24 06:10 PM
GIVEN BRUCE DChief Operating OfficerJan 06Sale60.1335,6132,141,285858,993Jan 08 06:35 PM
O'Brien PatrickGeneral CounselJan 06Sale60.1214,625879,261258,375Jan 08 06:33 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 06Sale60.1120,0001,202,201391,185Jan 08 06:31 PM
Anzalone Christopher RichardChief Executive OfficerDec 24Sale63.5083,3335,291,6461,805,237Dec 27 04:54 PM
Anzalone Christopher RichardChief Executive OfficerDec 13Sale66.7383,3335,560,4891,888,570Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 12Sale67.50100,0006,749,6301,971,903Dec 13 06:35 PM
Anzalone Christopher RichardChief Executive OfficerDec 03Sale61.5812,033740,9522,071,903Dec 04 06:48 PM
Anzalone Christopher RichardChief Executive OfficerDec 02Sale69.1537,9672,625,5702,083,936Dec 04 06:48 PM